Featured Research

from universities, journals, and other organizations

New Therapeutic Option For Human Hepatocyte Cancer

Date:
September 23, 2008
Source:
World Journal of Gastroenterology
Summary:
A group from Germany found that using H-1 parvovirus infection and chemotherapeutic treatment can enhance the cytotoxic effect of anti-cancer agents. Furthermore H-1 PV induces the expression of tumor suppressors such as p53 or promyelocytic leukemia protein, thus increased the suscebtibility to cell death in H-1 PV-infected tumor cells.

A group from Germany found that using H-1 parvovirus infection and chemotherapeutic treatment can enhance the cytotoxic effect of anti-cancer agents. Furthermore H-1 PV induces the expression of tumor suppressors such as p53 or promyelocytic leukemia protein, thus increased the suscebtibility to cell death in H-1 PV-infected tumor cells.

p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities. So H-1 PV is a suitable agent to circumvent the resistance of p53-negative human hepatocellular carcinoma (HCC) cells to genotoxic agents, and enhances the apoptotic process which is dependent on functional PML. Thus, H-1 PV may be considered as therapeutic options for HCC, especially for p53-negative tumors.

The research team led by Prof. Markus Moehler from First Department of Internal Medicine of Johannes Gutenberg University of Mainz evaluated the synergistic targeting and killing of human HCC cells lacking p53 by the oncolytic autonomous PV H-1 with chemotherapeutic agents. This was published on 28 June 2008, in the World Journal of Gastroenterology.

Their result shows that parvovirus H-1 PV triggers an apoptotic type of death in human HCC cells, and that p53 is dispensable for this process. In contrast, PML, which is induced by H-1 PV infection, helps the parvovirus to kill the carcinoma cells, irrespective of their p53 status. Given the known dependence of apoptosis induction by radio-chemotherapeutic agents on the p53 status of target cells, parvoviruses appear to be suitable adjuvants to eliminate tumor cell populations with resistance against these agents by means of combined treatments. Parvovirus H-1 will be a new option for patients with human HCC and clinical phase I-II trials with these oncolytic gene therapy vectors should be done in the near future.

Many viruses are known to be pathogenic and increase carcinogenesis. In the contrary, the autonomous parvoviruses destroy tumors, activate the immune system and may thus even be good for the health of men.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Moehler M. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires PML. World J Gastroenterol, 14(24): 3819-3828 [link]

Cite This Page:

World Journal of Gastroenterology. "New Therapeutic Option For Human Hepatocyte Cancer." ScienceDaily. ScienceDaily, 23 September 2008. <www.sciencedaily.com/releases/2008/09/080923104309.htm>.
World Journal of Gastroenterology. (2008, September 23). New Therapeutic Option For Human Hepatocyte Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/09/080923104309.htm
World Journal of Gastroenterology. "New Therapeutic Option For Human Hepatocyte Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080923104309.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins